Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	159
Overall Study	STARTED	Sotagliflozin 400 mg	317
Overall Study	STARTED	Sotagliflozin 200 mg	160
Overall Study	STARTED	Glimepiride	318
Overall Study	COMPLETED	Placebo	125
Overall Study	COMPLETED	Sotagliflozin 400 mg	266
Overall Study	COMPLETED	Sotagliflozin 200 mg	128
Overall Study	COMPLETED	Glimepiride	270
Overall Study	NOT COMPLETED	Placebo	34
Overall Study	NOT COMPLETED	Sotagliflozin 400 mg	51
Overall Study	NOT COMPLETED	Sotagliflozin 200 mg	32
Overall Study	NOT COMPLETED	Glimepiride	48

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03332771/flow